Interferon‐γ in healthy subjects: selective modulation of inflammatory mediators
- 1 June 2001
- journal article
- clinical trial
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 31 (6), 536-543
- https://doi.org/10.1046/j.1365-2362.2001.00833.x
Abstract
Background It is suggested that interferon‐γ (IFN‐γ), like other cytokines, is a mediator in the host inflammatory response, which could be of importance in the pathophysiology of sepsis. The role of IFN‐γ in human host inflammatory responses, however, has not been studied. Design In a placebo‐controlled trial we studied the acute effects of IFN‐γ administration on host inflammatory mediators in healthy men: i.e. the cytokine/chemokine cascade system, acute‐phase proteins, activation markers of the innate cellular immunity and coagulation/fibrinolysis parameters. Results IFN‐γ increased plasma levels of interleukin‐6 (IL‐6), IL‐8 and IFN‐γ‐inducible protein‐10 (IP‐10) (P < 0·05), but did not affect plasma levels of other cytokines (IL‐4, IL‐10, tumour necrosis factor‐α, IL‐12p40/p70). Plasma concentrations of C‐reactive protein and secretory phospholipase A2 both increased (P < 0·05). Plasma levels of the leucocyte activation marker elastase‐α1–antitrypsin complexes increased after IFN‐γ administration (P < 0·05), IFN‐γ increased the percentage of high‐affinity Fcγ‐receptor (FcγRI) ‐positive neutrophils (P < 0·05), but did not affect the mean fluorescence intensity of FcγRI on neutrophils. Procoagulant and profibrinolytic effects of IFN‐γ were evidenced by increased plasma levels of prothrombin fragment F1 + F2, tissue‐plasminogen activator and plasmin‐α2–antiplasmin complexes (P < 0·05). Conclusion We conclude that IFN‐γ selectively affects host inflammatory mediators in humans.Keywords
This publication has 53 references indexed in Scilit:
- Human Chemokines: An UpdateAnnual Review of Immunology, 1997
- A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cellsImmunology Today, 1997
- The cytokine‐mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemiaEuropean Journal of Clinical Investigation, 1997
- Therapy with interleukin-2 induces the systemic release of phospholipase-A 2Cancer Immunology, Immunotherapy, 1995
- Interleukin‐12 is required for interferon‐γ production and lethality in lipopolysaccharide‐induced shock in miceEuropean Journal of Immunology, 1995
- Alpha- and Gamma-lnterferon Inhibit Plasminogen Activator Inhibitor-1 Gene Expression in Human Retinal Pigment Epithelial CellsOphthalmic Research, 1994
- Complement activation during OKT3 treatment: A possible explanation for respiratory side effectsKidney International, 1993
- Activation of Coagulation after Administration of Tumor Necrosis Factor to Normal SubjectsNew England Journal of Medicine, 1990
- Tumor Necrosis Factor and Interleuktn-1 in the Serum of Children with Severe Infectious PurpuraNew England Journal of Medicine, 1988
- Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes.Journal of Clinical Investigation, 1983